Filing Flows › 8-K events › Korro Bio
Korro Bio: results of operations
Form 8-K filed Nov 5, 2026 · items 1.02, 2.02
Results of operationsKorro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
What the filing says
Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR)
Read the filing on SEC EDGAR →
What usually followsAcross 2,368 8-Ks reporting Item 1.02 (termination of a material agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.5%, up 51% of the time); over the following 21 sessions, +1.1%. Item 2.02: +0.2% next session across 69,115. Every item ranked →
What this kind of filing means
Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.
Korro Bio at a glance
Korro Bio, Q4 2025: revenue $1.3M (-43% year over year). The chart follows the revenue to costs, profit and cash.
Korro Bio: every quarter, Q/Q and Y/Y, holders and guidance →
Korro Bio’s other material 8-Ks
- Oct 22, 2026 — FDA decisions Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung an
Other recent earnings
- Airsculpt Technologies Nov 6, 2026
- Terawulf Nov 6, 2026
- Plains GP Holdings LP Nov 6, 2026
- Entera Bio Nov 6, 2026
- PSQ Holdings Nov 6, 2026
- Ziff Davis Nov 6, 2026
- Plains All American Pipeline LP Nov 6, 2026
- Concentra Group Holdings Parent Nov 5, 2026
- Conduent Nov 5, 2026
- Installed Building Products Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.